586 related articles for article (PubMed ID: 33985931)
1. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Togano T; Andoh S; Komuro M; Mitsui Y; Itoi S; Hirai R; Nakamura M; Tanimura A; Sekine R; Takeshita M; Miwa A; Hagiwara S
Intern Med; 2022 Nov; 61(22):3329-3334. PubMed ID: 35466165
[TBL] [Abstract][Full Text] [Related]
3. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
4. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
5. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.
Gerrie AS; Mikhael JR; Cheng L; Jiang H; Kukreti V; Panzarella T; Reece D; Stewart KA; Trieu Y; Trudel S; Chen CI
Br J Haematol; 2013 Jun; 161(6):802-10. PubMed ID: 23594335
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
8. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
10. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; San Miguel J; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2039-2051. PubMed ID: 26428082
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma.
Kauer J; Sester LS; Kriegsmann K; Weinhold N; Ober M; Müller-Tidow C; Goldschmidt H; Raab MS; Sauer S
Hematol Oncol; 2023 Aug; 41(3):453-462. PubMed ID: 36680428
[TBL] [Abstract][Full Text] [Related]
13. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
15. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
17. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
